Effects of felodipine ER, a dihydropyridine calcium antagonist, on blood pressure and serum lipids

Current Medical Research and Opinion

Volumn 14, Issue 2, 1998, Pages 97-103

  Reuter, M K ^a   Lorenz, H ^b   Verho, P ^b   Smith, N ^c   Degen, A ^b   Verho, M ^c  

^a SANOFI   (France)

^b BBS   (Germany)

^c Hoechst Marion Roussel   (United States)

Author keywords

Antihypertensive efficacy; Felodipine; Lipids; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CALCIUM ANTAGONIST; CHOLESTEROL; FELODIPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PULSE RATE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031814655     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999809113348     Document Type: Article

References (22)

1. Assmann, G. and Scheftler, G. (1988). Diagnostik und Therapie der Hyperlipidämien. Dtsch. Ärtzebl., 85, C1324.
2. Baggio, E., Maraffi, F., Montalto, C., Conti, D., Ravera, E., Ottolini, S. and Gandini, R. (1995). The effects of felodipine and amlodipine on glucose and lipid metabolism in patients affected by non-insulin-dependent diabetes mellitus and hypertension. A comparative, randomized, parallel-group study. Curr. Ther. Res., 56, 1050-1058.
3. Becker, R. H. A., Linz, W., Wiemer, G. and Nordlander, M. (1991). Low-dose felodipine treatment attenuates endothelial dysfunction in rabbits fed an atherogenic diet. J. Cardiovasc. Pharmacol., 18, Suppl 10, S36-S41.
4. Blychert, E. (1992). Felodipine pharmacokinetics and plasma concentration vs effect relationships. Blood Press., Suppl 2, 1-30.
5. Büning, H. and Trenkler, G. (1978). Nichtparametrische statistische Methoden. de Gruyter, Berlin.
6. Clement, D. L. and De Pue, N. Y. (1985). Effect of felodipine and metoprolol on muscle and skin arteries in hypertensive patients. Drugs, 29, Suppl 2, 137-143.
7. DeQuattro, V. (1992). Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients. Clin. Exp. Hypertens., A14, 965-988.
8. DiBona, G. F. and Sawin, L. L. (1984). Renal tubular site of action of felodipine. J. Pharmacol. Exp. Ther., 228, 420-428.
9. Edgar, B., Bengtsson, B., Elmfeldt, D., Lundborg, P., Nyberg, G., Raner, S. and Rönn, O. (1985). Acute diuretic/natriuretic properties of felodipine in man. Drugs, 29, Suppl 2, 176-184.
10. Hedner, T., Elmfeldt, D., Dahlöf, C. and Sjögren, E. (1987). Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in patients with arterial hypertension. Drugs, 34, Suppl 3, 125-131.
11. Herlitz, H., Aurell, M. and Conradson, T. (1983). Felodipine, an arteriolar dilator with pronounced antihypertensive effect. Lancet, 1, 409-410.
12. Lassen, E., Ahlstrom, F., Bogeskov-Jensen, I., Frimodt-Moller, J., Rishoj Nielsen, M., Wickers-Nielsen, N. and Winkel, O. (1990). A comparison of felodipine and nitrendipine in the treatment of hypertension. J. Cardiovasc. Pharmacol., 15, Suppl 4, S94.
13. Ljung, B. (1985). Vascular selectivity of felodipine. Drugs, 29, Suppl 2, 46-58.
14. Medical Research Council Working Party (1985). MRC trial of treatment of mild hypertension: principal results. Br. Med. J., 291, 97-104.
15. Nielsen, M. R., Winkel, O. P., Ahlstrom, F., Frimodt-Moller, J., Bogeskov-Jensen, I., Wickers-Nielsen, N. and Lassen, E. (1992). Effects on plasma lipids during long term antihypertensive treatment with felodipine. Drug Invest., 4, 361-364.
16. Nilsson-Ehle, P., The Swedish MC study group (1990). Felodipine does not affect plasma lipoprotein concentrations. J. Cardiovasc. Pharmacol., 15, Suppl 4, S112.
17. Nilsson-Ehle P. (1988). Felodipine does not affect plasma lipoprotein concentrations. J. Cardiovasc. Pharmacol., 12, Suppl 6, S183.
18. Pocock, S. J. (1991). Clinical Trials: A Practical Approach. Wiley, New York.
19. Sachs, L. (1978). Angewandte Statistik. 5th edn, Springer-Verlag, Berlin.
20. Schersten, B. F. E. (1994). Unchanged lipid and lipoprotein concentrations in hypertensive patients with type II diabetes mellitus during one year of treatment with felodipine and nifedipine compared with placebo. Am. J. Hypertens., 7, 73A.
21. Schneider, J. (1991). Serum lipoproteins in hyperlipoproteinemic patients with essential hypertension treated with felodipine for two years. Curr. Ther. Res., 50, 118-126.
22. Shionoiri, H., Takizawa, T., Ohyama, Y., Ishii, J., Katayama, S., Nagasawa, T., Kitamoto, K., Nagasawa, K., Hariya, Y., Sato, R., Ito, T., Ishii, M., Felodipine Multicenter Prospective Study Group in Japan (1994). Felodipine therapy may not alter glucose and lipid metabolism in hypertensives. Hypertension, 23, Suppl I, I215-I219.